MedTrace Logo

Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

NCT03881501 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2019-03-19

No results posted yet for this study

Summary

It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.

Conditions

  • Hepatocellular Carcinoma Non-resectable

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xianglin Yuan, MD,PhD · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-05
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03881501 on ClinicalTrials.gov